Tags

Type your tag names separated by a space and hit enter

Dynamic evaluation of mesenchymal circulating tumor cells in patients with colorectal cancer: Clinical associations and prognostic value.
Oncol Rep. 2020 Aug; 44(2):757-767.OR

Abstract

Circulating tumor cells (CTCs), as the precursor of metastases, gain mesenchymal traits through the epithelial‑mesenchymal transition (EMT) process, thereby mediating tumor metastasis. However, the dynamic changes and clinical value of mesenchymal CTCs (MCTCs) in colorectal cancer (CRC) patients remain inconclusive. The aim of the present study was to explore the prognostic value of dynamic changes of MCTCs in CRC patients using our previously developed CTCBIOPSY® device with an immunocytochemistry assay. The results revealed that 74 out of 175 patients were pre‑MCTCs‑positive and 41 out of 127 patients were post‑MCTCs‑positive. Dynamical monitoring revealed that the status of MCTCs remained dynamically changed under the pressure of anticancer therapy, and these dynamic changes were significantly associated with lymphovascular invasion (P<0.001) and TNM stage (P=0.033). Moreover, Kaplan‑Meier survival analyses revealed that the median recurrence‑free survival (RFS) and overall survival (OS) were significantly different between four groups (pre‑MCTC‑→post‑MCTC‑; pre‑MCTC‑→post‑MCTC+; pre‑MCTC+→post‑MCTC‑; pre‑MCTC+→post‑MCTC+), and patients with pre‑MCTCs+→post‑MCTCs+ had a significant shorter RFS (P=0.001) and OS (P<0.001) than the others. Univariate and multivariate Cox regression analyses demonstrated that persistent positivity of MCTCs before and after anticancer therapy was an independent risk factor affecting the RFS (HR: 1.302, 95%CI: 1.033‑1.639, P=0.025) and OS (HR: 1.366, 95%CI: 1.070‑1.742, P=0.012) of CRC patients. Collectively, these findings provided the evidence that the dynamic change of MCTCs during anticancer therapy can be a useful prognostic tool in CRC, indicating the important value of molecular profiling of CTCs‑EMT traits in cancer management.

Authors+Show Affiliations

Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.Department of Equipment Research and Development, Wuhan YZY Medical Science and Technology Co., Ltd., Wuhan, Hubei 430075, P.R. China.Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32627039

Citation

Shi, Dong-Dong, et al. "Dynamic Evaluation of Mesenchymal Circulating Tumor Cells in Patients With Colorectal Cancer: Clinical Associations and Prognostic Value." Oncology Reports, vol. 44, no. 2, 2020, pp. 757-767.
Shi DD, Yang CG, Han S, et al. Dynamic evaluation of mesenchymal circulating tumor cells in patients with colorectal cancer: Clinical associations and prognostic value. Oncol Rep. 2020;44(2):757-767.
Shi, D. D., Yang, C. G., Han, S., Wang, S. Y., & Xiong, B. (2020). Dynamic evaluation of mesenchymal circulating tumor cells in patients with colorectal cancer: Clinical associations and prognostic value. Oncology Reports, 44(2), 757-767. https://doi.org/10.3892/or.2020.7629
Shi DD, et al. Dynamic Evaluation of Mesenchymal Circulating Tumor Cells in Patients With Colorectal Cancer: Clinical Associations and Prognostic Value. Oncol Rep. 2020;44(2):757-767. PubMed PMID: 32627039.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dynamic evaluation of mesenchymal circulating tumor cells in patients with colorectal cancer: Clinical associations and prognostic value. AU - Shi,Dong-Dong, AU - Yang,Chao-Gang, AU - Han,Song, AU - Wang,Shu-Yi, AU - Xiong,Bin, Y1 - 2020/05/29/ PY - 2019/11/03/received PY - 2020/04/22/accepted PY - 2020/7/7/entrez PY - 2020/7/7/pubmed PY - 2020/7/7/medline SP - 757 EP - 767 JF - Oncology reports JO - Oncol. Rep. VL - 44 IS - 2 N2 - Circulating tumor cells (CTCs), as the precursor of metastases, gain mesenchymal traits through the epithelial‑mesenchymal transition (EMT) process, thereby mediating tumor metastasis. However, the dynamic changes and clinical value of mesenchymal CTCs (MCTCs) in colorectal cancer (CRC) patients remain inconclusive. The aim of the present study was to explore the prognostic value of dynamic changes of MCTCs in CRC patients using our previously developed CTCBIOPSY® device with an immunocytochemistry assay. The results revealed that 74 out of 175 patients were pre‑MCTCs‑positive and 41 out of 127 patients were post‑MCTCs‑positive. Dynamical monitoring revealed that the status of MCTCs remained dynamically changed under the pressure of anticancer therapy, and these dynamic changes were significantly associated with lymphovascular invasion (P<0.001) and TNM stage (P=0.033). Moreover, Kaplan‑Meier survival analyses revealed that the median recurrence‑free survival (RFS) and overall survival (OS) were significantly different between four groups (pre‑MCTC‑→post‑MCTC‑; pre‑MCTC‑→post‑MCTC+; pre‑MCTC+→post‑MCTC‑; pre‑MCTC+→post‑MCTC+), and patients with pre‑MCTCs+→post‑MCTCs+ had a significant shorter RFS (P=0.001) and OS (P<0.001) than the others. Univariate and multivariate Cox regression analyses demonstrated that persistent positivity of MCTCs before and after anticancer therapy was an independent risk factor affecting the RFS (HR: 1.302, 95%CI: 1.033‑1.639, P=0.025) and OS (HR: 1.366, 95%CI: 1.070‑1.742, P=0.012) of CRC patients. Collectively, these findings provided the evidence that the dynamic change of MCTCs during anticancer therapy can be a useful prognostic tool in CRC, indicating the important value of molecular profiling of CTCs‑EMT traits in cancer management. SN - 1791-2431 UR - https://www.unboundmedicine.com/medline/citation/32627039/Dynamic_evaluation_of_mesenchymal_circulating_tumor_cells_in_patients_with_colorectal_cancer:_Clinical_associations_and_prognostic_value L2 - http://www.spandidos-publications.com/or/44/2/757 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.